Monica Valente

Siena, 53100, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma.

A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma.

Journal: Cancers
Published: December 12, 2025

Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma.

Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma.

Journal: Communications medicine
Published: August 19, 2025

Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team.

Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team.

Journal: European journal of cancer (Oxford, England : 1990)
Published: June 26, 2025

Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma.

Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma.

Journal: Future oncology (London, England)
Published: June 12, 2025

Immune-Checkpoint Inhibitors in Lung Neuroendocrine Tumors - A Systematic Review and Meta-Analysis.

Immune-Checkpoint Inhibitors in Lung Neuroendocrine Tumors - A Systematic Review and Meta-Analysis.

Journal: OncoTargets and therapy
Published: January 01, 2025

A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis.

A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis.

Journal: OncoTargets and therapy
Published: May 21, 2024

Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].

Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 09, 2024

Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.

Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 30, 2023

Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.

Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.

Journal: Endocrine
Published: November 15, 2023

From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma.

From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma.

Journal: OncoTargets and therapy
Published: January 16, 2023

Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop".

Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop".

Journal: OncoTargets and therapy
Published: July 26, 2022

Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.

Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.

Journal: Journal of translational medicine
Published: January 03, 2022
Showing 1-12 of 23

Last Updated: 09/26/2026